The world’s first self-adjusting insulin pump system for type 1 diabetes is now available in the UK

Medtronic Logo_1200

The MiniMed™ 670G system features Medtronic’s most advanced SmartGuard™ technology and most accurate4 continuous glucose monitor (CGM) – the Guardian™ Sensor 3

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the launch of the MiniMed™ 670G system, the world’s first self-adjusting insulin pump system1,2,3, in the UK. The MiniMed 670G system is the first and only system to automate and personalize the delivery of basal insulin 24 hours a day[i],3 and represents an important step towards a fully automated closed loop system.

The MiniMed 670G system features SmartGuard™ Auto Mode – the company’s most advanced SmartGuard technology and the most accurate[ii] continuous glucose monitor (CGM) – the Guardian™ Sensor 3. Unlike other pumps which provide a set dose of basal insulin throughout the day and night, or switch off completely if a glucose spike is predicted, the MiniMed 670G system learns the user’s body and adjusts the delivery of insulin automatically to stablise glucose levels and avoid sugar lows (hypoglycaemia) and sugar spikes (hyperglycaemia). This technology finds patterns and makes predictions – enabling the System to mimic some of the functions of a healthy pancreas by making microadjustments to insulin delivery every five minutes to stabilise glucose levels.4.5

This stablisation of glucose levels means that a patient’s time spent in a healthy glucose range (often referred to as ‘Time in Range’) is maximised. This can prevent both immediate and long-term complications such as coronary artery disease, heart attack, and stroke.6,7“The MiniMed 670G system’s ability to stabilize glucose levels automatically to help improve time in target glucose range, has the potential to make a positive impact on people living with type 1 diabetes – both from a clinical and quality of life perspective,” said Dr Lalantha Leelarathna, Consultant Diabetologist, Manchester Royal Infirmary. His colleague Dr Hood Thabit, also a Consultant Diabetologist at Manchester Royal Infirmary, continued “We have seen first-hand how it can help people with type 1 diabetes achieve improved glucose control and reduce their burden of hypoglycaemia at the same time.”

Karen Addington is UK Chief Executive of the type 1 diabetes charity JDRF. She said: “Type 1 diabetes can be tough to live with. But new technologies can reduce the burden, offering individuals and their families the chance to think less about the condition. JDRF provided initial funding that supported research into closed-loop systems, as part of its mission to provide life-changing treatments whilst researching the cure.”

The MiniMed 670G system is indicated for people with T1D who are 7 years and above and are using a Total Daily Dose (TDD) of > 8 units per day. The MiniMed™ 670G system is not indicated for use in pregnancy or Type 2 diabetes.

The system also exclusively features the CONTOUR® NEXT LINK 2.4 blood glucose monitoring system from Ascensia Diabetes Care.

Time in Range

Time in Range refers to the percentage of time people with type 1 diabetes spend in the optimal glycemic range of 70-180 mg/dL (3.9-10 mmol/L). The goal with diabetes management is to increase time spent in this healthy range and to minimize high and low blood glucose levels, which can lead to both immediate and long-term complications such as damage to blood vessels – increasing the risk of coronary artery disease, heart attack, and stroke. Damage to blood vessels can also lead to loss of vision, kidney disease, and nerve problems. Increasing the “Time in Range” over the long-term can be accomplished by using advances in diabetes therapies, like the MiniMed 670G system with SmartGuard technology, that automates basal insulin delivery.3,4

MiniMed™ 670G system

For patients: Access to the MiniMed 670G system

Some areas in the UK are already trained and are providing the system on the NHS, but it’s not a guarantee that your local area is offering it yet. Check with your diabetes nurse or doctor to see if it’s available and if you meet the criteria for a pump or CGM.

​​​Clinical criteria for both insulin pump and CGM systems can be found in NICE guidelines and local policies are in place for funding.

If funding isn’t available for you, you can self-fund the MiniMed 670G System. To find out more about self-funding and any support on offer, visit the Medtronic website.

To self-fund a Medtronic device you’ll still need to be supported by your healthcare team, so talk to your doctor or nurse if you want to know more about this option.

About the Diabetes Group at Medtronic (

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care, and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic

Medtronic plc (, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

About JDRF

JDRF is the leading global organisation funding type 1 diabetes research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications. To accomplish this, JDRF has invested more than £1 billion since our inception. We collaborate with the most talented minds to develop and deliver a pipeline of innovative therapies to people living with type 1 diabetes. Our staff and volunteers around the globe are dedicated to campaigning for our vision of a world without type 1 diabetes. For more information, please visit or follow us on Twitter: @JDRFUK.

About type 1 diabetes

  • Type 1 diabetes is a chronic, life-threatening condition that has a life-long impact on those diagnosed with it and their families. JDRF exists to find the cure for type 1 diabetes
  • Type 1 diabetes is an autoimmune condition which cannot be prevented, and is not linked to lifestyle
  • People with type 1 diabetes rely on multiple insulin injections or pump infusions every day just to stay alive, until we find the cure
  • It stays with people for the rest of their lives
  • Type 1 diabetes affects about 400,000 people in the UK, 29,000 of them children
    •  A child diagnosed with type 1 diabetes at the age of five faces up to 19,000 injections and 50,000 finger prick blood tests by the time they are 18

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.




Ascensia Diabetes Care and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

For detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events, please consult the device manual. For further information, contact your local Medtronic representative.

  1. Christiansen M, et al. Diabetes Technol Ther. 2017; 19(9): 1-11.
  2. Iturralde E, et all. The Diabetes Educator. 2017; 43(2):223 – 232.
  3. Christiansen M, et al. Diabetes Technol Ther. 2017; 19(9): 1-11.
  4. Bergenstal, R. M. et al. Jama. 2016; 316 (16): 1407 – 1408.
  5. Garg SK et al. Diabetes Technol Ther. 2017 Mar;19(3):155-163.
  6. DCCT/EDIC Research Group. Arch Intern Med. 2009;169(14):1307-1316.
  7. Skyler JS. et al. J. Endocrinol Metab Clin North Am. 1996;25(2):243-254.


Posted in